Shattuck Labs (STTK) Expected to Release Quarterly Earnings on Thursday

Shattuck Labs (NASDAQ:STTK) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Shattuck Labs to announce earnings of ($0.1241) per share for the quarter. Investors can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Monday, August 17, 2026 at 12:30 PM ET.

Shattuck Labs Stock Performance

STTK stock opened at $7.14 on Tuesday. The stock’s 50 day simple moving average is $6.22 and its 200 day simple moving average is $5.88. Shattuck Labs has a fifty-two week low of $0.71 and a fifty-two week high of $8.33. The company has a market cap of $547.50 million, a P/E ratio of -11.33 and a beta of 1.08.

Insider Transactions at Shattuck Labs

In related news, insider Abhinav A. Shukla sold 23,365 shares of Shattuck Labs stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $7.08, for a total transaction of $165,424.20. Following the sale, the insider directly owned 86,380 shares in the company, valued at approximately $611,570.40. This trade represents a 21.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Clay B. Siegall acquired 62,500 shares of the business’s stock in a transaction on Tuesday, June 9th. The stock was acquired at an average cost of $4.00 per share, for a total transaction of $250,000.00. Following the transaction, the director owned 318,608 shares of the company’s stock, valued at approximately $1,274,432. The trade was a 24.40% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have sold 53,875 shares of company stock worth $379,305 in the last 90 days. Insiders own 8.79% of the company’s stock.

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds and other institutional investors have recently made changes to their positions in STTK. Virtu Financial LLC bought a new position in Shattuck Labs during the third quarter valued at about $38,000. AQR Capital Management LLC raised its position in Shattuck Labs by 265.4% in the first quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after acquiring an additional 31,355 shares during the period. Qube Research & Technologies Ltd bought a new stake in Shattuck Labs in the second quarter worth about $44,000. Squarepoint Ops LLC purchased a new position in Shattuck Labs in the third quarter valued at about $46,000. Finally, Bridgeway Capital Management LLC boosted its stake in Shattuck Labs by 147.5% in the second quarter. Bridgeway Capital Management LLC now owns 92,300 shares of the company’s stock valued at $73,000 after acquiring an additional 55,000 shares during the last quarter. 58.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Cantor Fitzgerald assumed coverage on Shattuck Labs in a report on Monday, April 27th. They set an “overweight” rating for the company. Citigroup upgraded Shattuck Labs from a “neutral” rating to a “buy” rating and set a $7.00 target price on the stock in a report on Friday, June 5th. Needham & Company LLC lifted their price target on shares of Shattuck Labs from $14.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, June 8th. Jefferies Financial Group upgraded shares of Shattuck Labs to an “outperform” rating and set a $7.00 price target for the company in a research note on Friday, June 5th. Finally, Wedbush upped their price objective on shares of Shattuck Labs from $8.00 to $11.00 and gave the stock an “outperform” rating in a report on Friday, May 8th. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Shattuck Labs has an average rating of “Moderate Buy” and an average target price of $12.62.

Shattuck Labs Company Profile

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.